SOLAR-PROMOTION-GMBH
29.5.2024 14:04:30 CEST | Business Wire | Press release
The German government’s goal is to have an equal share of large-scale power plants and roof-mounted systems. In 2023, the large-scale ground-mounted segment was able to increase by 45 percent. With the adoption of Solar Package I, this segment will continue to grow. The package of measures aims to reduce the red tape associated with solar deployment in order to achieve an annual growth of 22 gigawatt peak from 2026. The latest applications, products and business models for large-scale PV power plants will be on display at Intersolar Europe, the world’s leading exhibition for the solar industry. It will be held in Munich from June 19–21 as part of The smarter E Europe, the continent’s largest alliance of exhibitions for the energy industry. Some 3,000 exhibitors and over 115,000 visitors from all corners of the globe are expected to attend. The event will take place across 19 exhibition halls and an Outdoor Area.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240529516051/en/
Intersolar Europe presents innovations in the field of hybrid systems. (© Solar Promotion GmbH)
Hybrid power plants consisting of PV and wind power or storage, or both, offer various benefits: Sun and wind complement each other’s generation profiles and can be combined in a system, making optimal use of energy infrastructure such as interconnection points and the space required to implement the system. The combination with energy storage comes with additional advantages: It can smooth out the volatility of renewables, and the stored electricity can be fed into the grid when it is needed – or it can be traded for a profit. Energy arbitrage enables the targeted provision and marketing of solar and wind energy on the energy exchange. The electricity is stored when the price is low or a lot of renewable electricity is being produced. When it is profitable to sell the stored electricity, it is fed into the grid.
The latest technologies in operation and maintenance
Artificial intelligence (AI) is all the rage right now. It is also increasingly being used in the solar industry, especially in operations and maintenance (O&M). The AI-driven detection and analysis of incidents and deviations in operations and the standardized creation and selection of tickets are processes in which AI can be used to quickly process large amounts of data. In O&M, AI helps free up human resources for more complex tasks and standardize operations. What’s more, AI-supported software solutions can process weather data and create generation forecasts.
Special solar systems: parking lot PV, agricultural PV and floating PV
With Solar Package I, the “special solar systems” defined in the German Renewable Energy Sources Act EEG now have their own tender segment. These applications are becoming more prevalent and dual land use concepts are coming to the forefront of solar deployment plans. The maximum value for tenders has been raised to 9.5 cents/kWh. The products in this segment are rapidly evolving: carport substructures, elevated vertical and horizontal solar technology with and without trackers for agricultural PV, and mounting solutions for floating PV.
Intersolar Europe
As the world’s leading exhibition for the solar industry, Intersolar Europe demonstrates the enormous vitality of the solar market. For more than 30 years, it has been providing a networking opportunity for key players, focusing on the latest trends, developments and business models under the motto “Connecting Solar Business”. Intersolar Europe will take place from June 19–21, 2024 as part of The smarter E Europe at Messe München.
For more information, please visit: www.intersolar.de.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240529516051/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr
Beerenberg Prevails in Patent Case Against Aspen Aerogels29.6.2026 07:00:00 CEST | Press release
The ruling confirms that Beerenberg did not infringe Aspen Aerogels’ patents. The Korean Patent Court has invalidated three of Aspen Aerogels’ patents related to improved hydrophobic aerogel material. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260628192007/en/ Beerenberg delivers high-end insulation solutions built for performance, reliability, and long-term value. (Photo: Beerenberg) The ruling confirms the conclusion of the Intellectual Property Trial and Appeal Board (IPTAB) that the patents did not meet the necessary requirements for patentability. Beerenberg, which specializes in high-end insulation products, welcomes the court’s decision. “We are pleased that the case has now been concluded and that any uncertainty regarding the infringement claims has been removed,” says CEO Arild Apelthun. About Beerenberg Beerenberg has delivered cost-efficient solutions to a wide range of industrial enterprises for 49 years. Th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom